Frazier Life Sciences Management’s Mereo BioPharma MREO Stock Holding History

Frazier Life Sciences Management’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,440,112	Closed	-$19.4M	–	48
2025 Q3	$19.4M	Hold	9,440,112	–	–	0.58%	30
2025 Q2	$25.6M	Buy	9,440,112 +1,620,249	+21%	+$3.91M	1.02%	22
2025 Q1	$17.6M	Buy	7,819,863 +2,722,084	+53%	+$7.7M	0.8%	26
2024 Q4	$17.8M	Hold	5,097,779	–	–	0.74%	28
2024 Q3	$21M	Buy	5,097,779 +696,408	+16%	+$2.88M	0.84%	26
2024 Q2	$15.8M	Buy	+4,401,371	New	+$14.3M	0.74%	31

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Frazier Life Sciences Management's MREO Position: Q4 2025 in Review

Frazier Life Sciences Management sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 9,440,112 shares — an estimated $19.4M sold.

Frazier Life Sciences Management first reported a position in MREO in Q2 2024 and held it in 6 quarters. The position peaked at $25.6M in Q2 2025. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

Frazier Life Sciences Management reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
Frazier Life Sciences Management sold 9,440,112 Mereo BioPharma shares in Q4 2025, an estimated $19.4M.
Frazier Life Sciences Management first reported a position in Mereo BioPharma in Q2 2024 and held it in 6 quarters.
Frazier Life Sciences Management's Mereo BioPharma position peaked at $25.6M in Q2 2025.
70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on Frazier Life Sciences Management's 13F filing for Q4 2025, filed 13 Feb 2026.